Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Blueprint Medicines (BPMC)
NASDAQ:BPMC
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.45Last Year’s EPS
1.45Same Quarter Last Year
Moderate Buy
Based on 15 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 13, 2025
|% Change Since: -10.92%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Positive
The earnings call was predominantly positive, with strong revenue growth and market expansion for AYVAKIT, successful international progress, promising development of BLU-808, and financial discipline. However, some challenges in Q1 2025 and a heavy reliance on the U.S. market were noted.Company Guidance
During the Blueprint Medicines 4Q and FY 2024 earnings call, the company provided robust guidance for 2025, projecting AYVAKIT's revenue to reach $680 million to $710 million, reflecting an impressive 45% growth at the midpoint. This follows a notable annual growth of 135% in 2024, with product revenue hitting $479 million. The company's leadership anticipates a long-term target of $2 billion in revenue by 2030, bolstered by a growing market for systemic mastocytosis treatment. They emphasized the low penetration of AYVAKIT among currently diagnosed patients, suggesting substantial room for growth. Additionally, the company expects the systemic mastocytosis franchise, anchored by AYVAKIT, to eventually reach a peak value of $4 billion. To achieve these goals, Blueprint Medicines plans to expand its commercial and medical field infrastructure, invest in market-building initiatives, and advance its pipeline, including the next-generation KIT D816V inhibitor, elenestinib, and the promising BLU-808, aimed at a range of mast cell-mediated allergic inflammatory diseases.AYVAKIT Revenue Growth
In 2024, AYVAKIT achieved $479 million in product revenue, representing impressive annual growth of 135%. The company expects AYVAKIT to achieve $680 million to $710 million in revenue in 2025, with a projected 45% growth rate at the midpoint.
Increased Market Opportunity
Blueprint Medicines identified a larger SM market than previously thought, with new epidemiology data suggesting a twofold increase in potential SM patients in the U.S., from approximately 30,000 to 60,000 patients.
International Expansion
The company obtained ISM pricing for AYVAKIT in Germany and plans to launch in additional European markets, with significant international revenue growth expected.
BLU-808 Clinical Development
Positive healthy volunteer data for BLU-808 showing a wide therapeutic index and promising pharmacodynamics, with proof-of-concept studies planned for multiple allergic and inflammatory diseases.
Financial Discipline
Blueprint Medicines reported a significant reduction in cash burn, with operating expenses reduced in 2024 compared to 2023, and expects operating cash burn to continue to decline in 2025.
---
BPMC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BPMC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 13, 2025 | $103.56 | $95.19 | -8.08% |
| Oct 30, 2024 | $83.40 | $89.24 | +7.00% |
| Aug 01, 2024 | $108.30 | $100.29 | -7.40% |
| May 02, 2024 | $94.86 | $107.00 | +12.80% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Blueprint Medicines (BPMC) report earnings?
Blueprint Medicines (BPMC) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Blueprint Medicines (BPMC) earnings time?
Blueprint Medicines (BPMC) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BPMC EPS forecast?
BPMC EPS forecast for the fiscal quarter 2025 (Q1) is -0.45.
---